Standard
Manufacture of adoptive cell therapies at academic cancer centers : scientific, safety and regulatory challenges. / Saini, K. S.; Svane, I. M.; Juan, M.; Barlesi, F.; André, F.
I:
Annals of Oncology, Bind 33, Nr. 1, 2022, s. 6-12.
Publikation: Bidrag til tidsskrift › Leder › Forskning › fagfællebedømt
Harvard
Saini, KS
, Svane, IM, Juan, M, Barlesi, F & André, F 2022, '
Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges',
Annals of Oncology, bind 33, nr. 1, s. 6-12.
https://doi.org/10.1016/j.annonc.2021.09.020APA
Saini, K. S.
, Svane, I. M., Juan, M., Barlesi, F., & André, F. (2022).
Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges.
Annals of Oncology,
33(1), 6-12.
https://doi.org/10.1016/j.annonc.2021.09.020Vancouver
Saini KS
, Svane IM, Juan M, Barlesi F, André F.
Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges.
Annals of Oncology. 2022;33(1):6-12.
https://doi.org/10.1016/j.annonc.2021.09.020Author
Saini, K. S. ; Svane, I. M. ; Juan, M. ; Barlesi, F. ; André, F. / Manufacture of adoptive cell therapies at academic cancer centers : scientific, safety and regulatory challenges. I: Annals of Oncology. 2022 ; Bind 33, Nr. 1. s. 6-12.
Bibtex
@article{de0193269a7d43f693071a2c011e4192,
title = "Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges",
author = "Saini, {K. S.} and Svane, {I. M.} and M. Juan and F. Barlesi and F. Andr{\'e}",
note = "Funding Information: The authors acknowledge the critical review and comments from Brian Hamilton and Carla Sterk of Labcorp Drug Development Inc. None declared. KSS reports consulting fees from the European Commission, and stock and/or other ownership interests in Labcorp Inc. and Quantum Health Analytics SPRL, outside the submitted work. IMS reports advisory board or invited speaker engagement from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, and Roche; stock and/or other ownership interests in IO Biotech; and institutional grants from Adaptimmune, Enara Bio, Evaxion, Lytix Biopharma, and TILT Biotherapeutics, outside the submitted work. FA reports research funding to his institution from AstraZeneca, Novartis, Pfizer, Eli Lilly, Roche; and travel, accommodations, and expenses from Novartis, Roche, GlaxoSmithKline, AstraZeneca, outside the submitted work. All other authors have declared no conflicts of interest.",
year = "2022",
doi = "10.1016/j.annonc.2021.09.020",
language = "English",
volume = "33",
pages = "6--12",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",
}
RIS
TY - JOUR
T1 - Manufacture of adoptive cell therapies at academic cancer centers
T2 - scientific, safety and regulatory challenges
AU - Saini, K. S.
AU - Svane, I. M.
AU - Juan, M.
AU - Barlesi, F.
AU - André, F.
N1 - Funding Information:
The authors acknowledge the critical review and comments from Brian Hamilton and Carla Sterk of Labcorp Drug Development Inc. None declared. KSS reports consulting fees from the European Commission, and stock and/or other ownership interests in Labcorp Inc. and Quantum Health Analytics SPRL, outside the submitted work. IMS reports advisory board or invited speaker engagement from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, and Roche; stock and/or other ownership interests in IO Biotech; and institutional grants from Adaptimmune, Enara Bio, Evaxion, Lytix Biopharma, and TILT Biotherapeutics, outside the submitted work. FA reports research funding to his institution from AstraZeneca, Novartis, Pfizer, Eli Lilly, Roche; and travel, accommodations, and expenses from Novartis, Roche, GlaxoSmithKline, AstraZeneca, outside the submitted work. All other authors have declared no conflicts of interest.
PY - 2022
Y1 - 2022
U2 - 10.1016/j.annonc.2021.09.020
DO - 10.1016/j.annonc.2021.09.020
M3 - Editorial
C2 - 34655734
AN - SCOPUS:85119202290
VL - 33
SP - 6
EP - 12
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 1
ER -
